Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Galapagos ADRs Down After Study Data

07/15/2021 | 11:49am EDT

By Michael Dabaie

Galapagos NV ADRs were down 13% to $57.40 after reporting data from several studies.

The Belgium-based biotechnology company said it had positive topline results with tyrosine kinase 2 inhibitor GLPG3667 in a Phase 1b study in psoriasis. The company said the study showed positive efficacy signal at week 4 and the data support initiation of Phase 2b dose finding study in psoriasis.

Galapagos also reported topline results with salt inducible kinase 2/3 inhibitor GLPG3970 in three patient studies. These were a Phase 1b study in moderate to severe psoriasis and two Phase 2a studies in moderate to severely active ulcerative colitis and rheumatoid arthritis.

The study in psoriasis patients showed improvement in Psoriasis Area and Severity Index score at Week 6.

The study in ulcerative colitis patients shows signs of "biologically important effects," but these findings didn't translate in a differentiation from placebo on change from baseline total Mayo Clinic Score, the company said.

In the rheumatoid arthritis study, at week 6 patients on GLPG3970 showed no differentiation from placebo on the majority of efficacy endpoints, Galapagos said.

"The data will be presented with greater detail during the 2Q21 earnings call, but based upon the initial data disclosed, it seems likely that both the GLPG3970 and GLPG3667 programs will move into the next phase of clinical studies for psoriasis, respectively," Raymond James said in a note.

J.P. Morgan called the GLPG3667 "data somewhat encouraging, if undifferentiated," and said the GLPG3970 data was disappointing. "We believe the net of these two updates is negative," the firm said in an analyst note.

"On the basis of the data reported last night, we believe expectations for GLPG's TYK2 could be slightly increased, as the asset looks at least broadly in the same ballpark as [Bristol Myers Squibb's] far more advanced TYK2. However, we see potential for even heavily risk-adjusted SIK2/3 forecasts taken out of models, given failure of the lead asset, with the company now needing to take a follow-on into new clinical trials," J.P. Morgan said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

07-15-21 1148ET

All news about GALAPAGOS NV
09/21GALAPAGOS : increases share capital through subscription right exercises (Form 6-K)
PU
09/21GALAPAGOS : N.V., - Galapagos increases share capital through subscription right exercises
PU
09/21GALAPAGOS : Issues New Shares For Subscription Right Exercises
MT
09/20GALAPAGOS : increases share capital through subscription right exercises
AQ
09/20GALAPAGOS : ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA« (FILGOTINIB) FOR THE TREATMENT O..
PU
09/17GALAPAGOS : N.v., - galapagos announces positive chmp opinion for jyseleca« (filgotinib) f..
PU
09/17GALAPAGOS : Gets European Medicines Agency's Positive Opinion on Ulcerative Colitis Drug C..
MT
09/17GALAPAGOS : Says it Received European Medicines Agency Positive Opinion for Ulcerative Col..
MT
09/17GALAPAGOS : Announces positive chmp opinion for jyseleca« (filgotinib) for the treatment o..
AQ
09/17Galapagos Announces Positive CHMP Opinion for Jyseleca« for the Treatment of Adults wit..
CI
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Financials
Sales 2021 519 M 609 M 609 M
Net income 2021 -224 M -263 M -263 M
Net cash 2021 3 243 M 3 801 M 3 801 M
P/E ratio 2021 -15,0x
Yield 2021 -
Capitalization 2 984 M 3 494 M 3 497 M
EV / Sales 2021 -0,50x
EV / Sales 2022 -0,37x
Nbr of Employees 1 397
Free-Float 73,8%
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 45,53 €
Average target price 59,71 €
Spread / Average Target 31,1%
EPS Revisions
Managers and Directors
Onno van de Stolpe Chief Executive Officer
Bart Filius President & Chief Operating Officer
Raj B. Parekh Chairman
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV-43.43%3 494
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353